SCHEMBL3012820

SCHEMBL3012820

O=[N+]([O-])c1cc(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)c(F)c4)cs3)CC2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.59
ALDH1A1 P00352 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 5/20 0.51
USP2 O75604 1/20 0.51
RECQL P46063 1/20 0.51
HSD17B10 Q99714 1/20 0.51
VCAM1 P19320 3/20 0.51
NPBWR1 P48145 1/20 0.50
MCHR1 Q99705 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
AR P10275 1/20 0.44
MITF O75030 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001212 0.95 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3003816 0.94 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3001871 0.92 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3019652 0.90 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3006391 0.90 SMN1; SMN2 (0.63) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3016152 0.90 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3001171 0.90 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3018617 0.88 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3021281 0.88 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3653812 0.88 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.